Aimei Health Technology Co Ltd Financials
This page shows Aimei Health Technology Co Ltd (AFJK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported earnings are decoupled from core operations as the company shrinks its balance sheet and liquidity evaporates.
Across FY2024 and FY2025, net income stayed positive while operating income and operating cash flow stayed negative in both years, so reported profit was not being produced by the operating engine or converted into cash. That mismatch coincided with assets shrinking from$73.8M to$12.1M , which points more to balance-sheet unwinding than operating improvement.
Short-term liquidity looks extremely thin: FY2025 ended with just
The balance sheet did get smaller in a meaningful way, with total liabilities dropping from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Aimei Health Technology Co Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aimei Health Technology Co Ltd's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Aimei Health Technology Co Ltd passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Aimei Health Technology Co Ltd generates $-0.53 in operating cash flow (-$565K OCF vs $1.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Aimei Health Technology Co Ltd reported $1.1M in net income in fiscal year 2025. This represents a decrease of 58.5% from the prior year.
Cash & Balance Sheet
Aimei Health Technology Co Ltd held $3K in cash against $0 in long-term debt as of fiscal year 2025.
Aimei Health Technology Co Ltd had 6M shares outstanding in fiscal year 2025. This represents an increase of 187.9% from the prior year.
Margins & Returns
Capital Allocation
AFJK Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$62K | N/A | -$130K-212.8% | -$42K+89.9% | -$413K | N/A | -$200K+35.3% | -$309K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | $45K | N/A | $352K-17.2% | $425K+130.1% | $185K | N/A | $744K+22.1% | $609K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AFJK Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.3M+1.6% | $12.1M-73.4% | $45.5M+2.0% | $44.6M+2.2% | $43.6M-40.9% | $73.8M+1.4% | $72.8M+1.2% | $71.9M |
| Current Assets | $19K+538.7% | $3K-88.3% | $25K-44.1% | $45K+456.4% | $8K-73.6% | $30K-75.5% | $124K-39.4% | $204K |
| Cash & Equivalents | $19K+532.2% | $3K-1.7% | $3K+39.3% | $2K-70.9% | $7K-74.0% | $28K-72.8% | $104K-34.3% | $158K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.5M+2.0% | $16.2M-67.0% | $48.9M+3.1% | $47.4M+3.1% | $46.0M-38.9% | $75.3M+2.3% | $73.6M+1.5% | $72.5M |
| Current Liabilities | $3.5M+4.3% | $3.4M+21.5% | $2.8M+25.3% | $2.2M+31.3% | $1.7M+106.3% | $817K+254.0% | $231K+107.5% | $111K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$4.2M-3.2% | -$4.1M-18.0% | -$3.4M-20.3% | -$2.9M-20.8% | -$2.4M-60.3% | -$1.5M-85.3% | -$797K-33.5% | -$597K |
| Retained Earnings | -$4.2M-3.2% | -$4.1M-18.0% | -$3.4M-20.3% | -$2.9M-20.8% | -$2.4M-60.3% | -$1.5M-85.3% | -$797K-33.5% | -$597K |
AFJK Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$75K-72.6% | -$43K+55.0% | -$96K+52.4% | -$202K+9.9% | -$224K-14.8% | -$195K-261.7% | -$54K+78.9% | -$256K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$69K-100.2% | $33.7M+7587.1% | -$450K0.0% | -$450K-101.5% | $30.8M | N/A | N/A | N/A |
| Financing Cash Flow | $159K+100.5% | -$33.6M-6252.1% | $547K-15.4% | $647K+102.1% | -$30.6M | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $34.1M | $0 | $0-100.0% | $31.3M | N/A | N/A | N/A |
AFJK Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.4% | N/A | 0.8%-0.2pp | 0.9%+0.5pp | 0.4% | N/A | 1.0%+0.2pp | 0.9% |
| Current Ratio | 0.010.0 | 0.000.0 | 0.01-0.0 | 0.02+0.0 | 0.00-0.0 | 0.04-0.5 | 0.54-1.3 | 1.84 |
| Debt-to-Equity | -3.93+0.0 | -3.98+10.2 | -14.22+2.4 | -16.58+2.8 | -19.42+31.6 | -50.99+41.3 | -92.34+29.2 | -121.50 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Aimei Health Technology Co Ltd profitable?
Yes, Aimei Health Technology Co Ltd (AFJK) reported a net income of $1.1M in fiscal year 2025.
What is Aimei Health Technology Co Ltd's operating cash flow?
Aimei Health Technology Co Ltd (AFJK) generated -$565K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aimei Health Technology Co Ltd's total assets?
Aimei Health Technology Co Ltd (AFJK) had $12.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Aimei Health Technology Co Ltd's current ratio?
Aimei Health Technology Co Ltd (AFJK) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aimei Health Technology Co Ltd's debt-to-equity ratio?
Aimei Health Technology Co Ltd (AFJK) had a debt-to-equity ratio of -3.98 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aimei Health Technology Co Ltd's return on assets (ROA)?
Aimei Health Technology Co Ltd (AFJK) had a return on assets of 8.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aimei Health Technology Co Ltd's cash runway?
Based on fiscal year 2025 data, Aimei Health Technology Co Ltd (AFJK) had $3K in cash against an annual operating cash burn of $565K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aimei Health Technology Co Ltd's debt-to-equity ratio negative or unusual?
Aimei Health Technology Co Ltd (AFJK) has negative shareholder equity of -$4.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aimei Health Technology Co Ltd's Piotroski F-Score?
Aimei Health Technology Co Ltd (AFJK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aimei Health Technology Co Ltd's earnings high quality?
Aimei Health Technology Co Ltd (AFJK) has an earnings quality ratio of -0.53x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Aimei Health Technology Co Ltd?
Aimei Health Technology Co Ltd (AFJK) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.